- Home
- ABUS vs AMAL Comparison
ABUS vs AMAL Comparison
Compare ABUS & AMAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- AMAL
- Stock Information
- Founded
- ABUS 2005
- AMAL 1923
- Country
- ABUS United States
- AMAL United States
- Employees
- ABUS N/A
- AMAL N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- AMAL Commercial Banks
- Sector
- ABUS Health Care
- AMAL Finance
- Exchange
- ABUS Nasdaq
- AMAL Nasdaq
- Market Cap
- ABUS 711.2M
- AMAL 760.6M
- IPO Year
- ABUS N/A
- AMAL 2018
- Fundamental
- Price
- ABUS $4.46
- AMAL $28.30
- Analyst Decision
- ABUS Strong Buy
- AMAL Hold
- Analyst Count
- ABUS 2
- AMAL 2
- Target Price
- ABUS $5.00
- AMAL $33.00
- AVG Volume (30 Days)
- ABUS 930.7K
- AMAL 173.6K
- Earning Date
- ABUS 11-10-2025
- AMAL 10-23-2025
- Dividend Yield
- ABUS N/A
- AMAL 1.98%
- EPS Growth
- ABUS N/A
- AMAL N/A
- EPS
- ABUS N/A
- AMAL 3.32
- Revenue
- ABUS $15,416,000.00
- AMAL $306,912,000.00
- Revenue This Year
- ABUS $138.02
- AMAL $9.82
- Revenue Next Year
- ABUS N/A
- AMAL $11.11
- P/E Ratio
- ABUS N/A
- AMAL $8.53
- Revenue Growth
- ABUS 53.23
- AMAL 1.28
- 52 Week Low
- ABUS $2.71
- AMAL $25.03
- 52 Week High
- ABUS $5.10
- AMAL $38.19
- Technical
- Relative Strength Index (RSI)
- ABUS 54.42
- AMAL 57.08
- Support Level
- ABUS $4.26
- AMAL $26.03
- Resistance Level
- ABUS $4.61
- AMAL $28.78
- Average True Range (ATR)
- ABUS 0.20
- AMAL 0.80
- MACD
- ABUS -0.01
- AMAL 0.26
- Stochastic Oscillator
- ABUS 65.45
- AMAL 86.85
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management and trust and custody services.